H.C. Wainwright starts coverage of Entera Bio with 'buy' rating

Entera Bio

06/09/2022 17:32

** H.C. Wainwright and Co initiates coverage of Israel-based
drug developer Entera Bio Ltd  ENTX.O  with "buy" rating and PT
of $10 
    ** Brokerage believes co's two lead drug candidates EB613
and EB612 represent lucrative target markets that are poorly
served by existing treatment options
    ** Osteoporosis patients sorely need oral anabolic
intervention, and if FDA approves EB613, it could reach peak
sales of more than $2 bln in the U.S. alone by 2035 - H.C.
Wainwright 
    ** Says hypoparathyroidism market appears underserved, and
if FDA approves EB612, it could achieve peak U.S. sales of
nearly $350 mln by 2033 
    ** Brokerage says EB613 and EB612 could both be launched in
2026, with potential price erosion due to generic competition
starting in 2036 for EB613 and in 2034 for EB612

 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))